Broad inhibitors of tyrosine kinase receptors (RTKs), such as ponatinib, have been identified as SMARCB1-related therapies and particularly PDGFR and FGFR are expressed in rhabdoid tumors upon SMARCB1 loss [46,47]. This evidence concerns the gene NTRK1 and rhabdoid tumor.